Next Pharmaceuticals, Salinas, CA, has purchased worldwide distribution rights, along with all patents, trademarks and scientific knowledge for Sytrinol from KGK Synergize, London, ON. Sytrinol is currently sold through Proprietary Nutritionals Inc., Kearny, NJ, who holds distribution rights through December 31, 2013.
 
Sytrinol is a patented and proprietary formula derived from natural citrus and palm fruit extracts. It combines polymethoxylated flavones (PMFs) and delta, gamma, and alpha tocotrienols.
 
Clinical research has demonstrated that Sytrinol significantly aids in improving total cholesterol, LDL-cholesterol, and triglycerides up to 30%, 27%, and 34%, respectively, compared to placebo. Sytrinol has also been shown to increase HDL-cholesterol and is a powerful antioxidant. The ingredient has been granted self-affirmed GRAS (Generally Recognized as Safe) status.